DE69233691D1 - Oxycodonzusammensetzungen mit kontrollierter Freisetzung - Google Patents

Oxycodonzusammensetzungen mit kontrollierter Freisetzung

Info

Publication number
DE69233691D1
DE69233691D1 DE69233691T DE69233691T DE69233691D1 DE 69233691 D1 DE69233691 D1 DE 69233691D1 DE 69233691 T DE69233691 T DE 69233691T DE 69233691 T DE69233691 T DE 69233691T DE 69233691 D1 DE69233691 D1 DE 69233691D1
Authority
DE
Germany
Prior art keywords
mean
oxycodone
hrs
admin
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69233691T
Other languages
English (en)
Other versions
DE69233691T2 (de
Inventor
Benjamin Oshlack
Mark Chasin
John Joseph Minogue
Robert Francis Kaiko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mundipharma GmbH
Original Assignee
NAPP PHARMACEUTICAL HOLDINGS L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25178688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69233691(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by NAPP PHARMACEUTICAL HOLDINGS L filed Critical NAPP PHARMACEUTICAL HOLDINGS L
Application granted granted Critical
Publication of DE69233691D1 publication Critical patent/DE69233691D1/de
Publication of DE69233691T2 publication Critical patent/DE69233691T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
DE69233691T 1991-11-27 1992-11-25 Oxycodonzusammensetzungen mit kontrollierter Freisetzung Expired - Lifetime DE69233691T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/800,549 US5266331A (en) 1991-11-27 1991-11-27 Controlled release oxycodone compositions
US800549 1991-11-27

Publications (2)

Publication Number Publication Date
DE69233691D1 true DE69233691D1 (de) 2007-06-06
DE69233691T2 DE69233691T2 (de) 2008-01-24

Family

ID=25178688

Family Applications (10)

Application Number Title Priority Date Filing Date
DE69233326T Expired - Lifetime DE69233326T2 (de) 1991-11-27 1992-11-25 Oxycodonhaltige Zubereitungen mit gesteuerter Wirkstoffabgabe
DE69232837.8T Expired - Lifetime DE69232837T3 (de) 1991-11-27 1992-11-25 Oxycodonhaltiges Arzneimittel mit verzögerter Wirkstoffabgabe
DE69233778T Expired - Lifetime DE69233778D1 (de) 1991-11-27 1992-11-25 Oxycodonzusammensetzungen mit kontrollierter Freisetzung
DE69233328T Expired - Lifetime DE69233328T3 (de) 1991-11-27 1992-11-25 Oxycodonhaltige Arzneizusammensetzungen mit verzögerter Wirkstoffabgabe
DE69214802T Expired - Lifetime DE69214802T2 (de) 1991-11-27 1992-11-25 Oxycodon-zusammensetzungen mit kontrollierter freisetzung
DE69233691T Expired - Lifetime DE69233691T2 (de) 1991-11-27 1992-11-25 Oxycodonzusammensetzungen mit kontrollierter Freisetzung
DE9219234U Expired - Lifetime DE9219234U1 (de) 1991-11-27 1992-11-25 Oxycodon-Zusammensetzung mit kontrollierter Freisetzung
DE69233640T Expired - Lifetime DE69233640T2 (de) 1991-11-27 1992-11-25 Oxycodonsalzzusammensetzungen mit kontrollierter Freisetzung
DE69233327T Expired - Lifetime DE69233327T2 (de) 1991-11-27 1992-11-25 Oxycodonhaltige Arzneizusammensetzungen mit verzögerter Wirkstoffabgabe
DE69233699T Expired - Lifetime DE69233699T2 (de) 1991-11-27 1992-11-25 Oxycodonzusammensetzungen mit kontrollierter Freisetzung

Family Applications Before (5)

Application Number Title Priority Date Filing Date
DE69233326T Expired - Lifetime DE69233326T2 (de) 1991-11-27 1992-11-25 Oxycodonhaltige Zubereitungen mit gesteuerter Wirkstoffabgabe
DE69232837.8T Expired - Lifetime DE69232837T3 (de) 1991-11-27 1992-11-25 Oxycodonhaltiges Arzneimittel mit verzögerter Wirkstoffabgabe
DE69233778T Expired - Lifetime DE69233778D1 (de) 1991-11-27 1992-11-25 Oxycodonzusammensetzungen mit kontrollierter Freisetzung
DE69233328T Expired - Lifetime DE69233328T3 (de) 1991-11-27 1992-11-25 Oxycodonhaltige Arzneizusammensetzungen mit verzögerter Wirkstoffabgabe
DE69214802T Expired - Lifetime DE69214802T2 (de) 1991-11-27 1992-11-25 Oxycodon-zusammensetzungen mit kontrollierter freisetzung

Family Applications After (4)

Application Number Title Priority Date Filing Date
DE9219234U Expired - Lifetime DE9219234U1 (de) 1991-11-27 1992-11-25 Oxycodon-Zusammensetzung mit kontrollierter Freisetzung
DE69233640T Expired - Lifetime DE69233640T2 (de) 1991-11-27 1992-11-25 Oxycodonsalzzusammensetzungen mit kontrollierter Freisetzung
DE69233327T Expired - Lifetime DE69233327T2 (de) 1991-11-27 1992-11-25 Oxycodonhaltige Arzneizusammensetzungen mit verzögerter Wirkstoffabgabe
DE69233699T Expired - Lifetime DE69233699T2 (de) 1991-11-27 1992-11-25 Oxycodonzusammensetzungen mit kontrollierter Freisetzung

Country Status (31)

Country Link
US (13) US5266331A (de)
EP (15) EP2243484A3 (de)
JP (2) JP3375960B2 (de)
KR (1) KR100280973B1 (de)
CN (2) CN1165307C (de)
AT (9) ATE261726T1 (de)
AU (1) AU657027B2 (de)
BG (1) BG61753B1 (de)
BR (1) BR9205498A (de)
CA (1) CA2098738C (de)
CZ (4) CZ300183B6 (de)
DE (10) DE69233326T2 (de)
DK (10) DK1810679T3 (de)
ES (9) ES2268189T3 (de)
FI (5) FI113152B (de)
GR (1) GR3022273T3 (de)
HK (6) HK1058474A1 (de)
HU (10) HU227516B1 (de)
IL (1) IL103909A (de)
MX (1) MX9302968A (de)
NO (6) NO307028B3 (de)
PH (1) PH31679A (de)
PL (2) PL172236B1 (de)
PT (8) PT722730E (de)
RO (1) RO115112B1 (de)
RS (3) RS50055B (de)
RU (1) RU2122411C1 (de)
SK (1) SK280295B6 (de)
WO (1) WO1993010765A1 (de)
YU (1) YU49495B (de)
ZA (1) ZA929227B (de)

Families Citing this family (296)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) † 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
IL119660A (en) * 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
EP1442745A1 (de) * 1993-10-07 2004-08-04 Euro-Celtique Oral anzuwendende opioidhaltige Zusammensetzungen mit verlängerter Wirkung
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US5811126A (en) * 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
US6159501A (en) * 1996-03-08 2000-12-12 Nycomed Danmark A/S Modified release multiple-units dosage composition for release of opioid compounds
WO1997045091A2 (en) * 1996-05-31 1997-12-04 Euro-Celtique, S.A. Sustained release oxycodone formulations with no fed/fast effect
JPH1050306A (ja) * 1996-07-31 1998-02-20 Toyota Autom Loom Works Ltd 水素吸蔵合金電極の製造方法
DE19710008A1 (de) * 1997-03-12 1998-09-17 Basf Ag Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
CN1204890C (zh) * 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
RU2241458C2 (ru) 1997-12-22 2004-12-10 Эро-Селтик, С.А. Комбинации агонист/антагонист опиоида
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
EP0955048A1 (de) * 1998-03-12 1999-11-10 Akzo Nobel N.V. Herstellung von Dosiereinheiten unter Anwendung einer Granulierung mit geringer Scherbeanspruchung
IL128818A0 (en) * 1998-03-12 2000-01-31 Akzo Nobel Nv Making dosage units using low shear granulation
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP2295043A1 (de) 1999-10-29 2011-03-16 Euro-Celtique S.A. Hydrocodon-Formulierungen mit gesteuerter Freisetzung
SK287684B6 (sk) * 1999-12-20 2011-06-06 Schering Corporation Pevná orálna farmaceutická dávková forma s predĺženým uvoľňovaním
AU2276801A (en) 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
JP2003522144A (ja) 2000-02-08 2003-07-22 ユーロ−セルティーク，エス．エイ． オピオイドアゴニストおよびアンタゴニストを含む制御放出組成物
CN101317825A (zh) 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 控释氢可酮制剂
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
JP2004534056A (ja) * 2001-06-08 2004-11-11 エンドー ファーマシューティカルズ， インコーポレイティド アクリルポリマーを使用する制御放出投薬形態、およびそれを作製するためのプロセス
EP1404331B1 (de) * 2001-07-06 2007-10-31 Penwest Pharmaceuticals Co. Verzögert freisetzende formulierungen von oxymorphon
EP2311460A1 (de) * 2001-07-06 2011-04-20 Endo Pharmaceuticals Inc. Kontrolliert freisetzende Formulierungen von Oxymorphon
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
SI1416842T1 (sl) 2001-07-18 2009-06-30 Euro Celtique Sa Farmacevtske kombinacije oksikodona in naloksona
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
WO2003015531A2 (en) * 2001-08-06 2003-02-27 Thomas Gruber Pharmaceutical formulation containing dye
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
ES2326794T3 (es) 2001-08-06 2009-10-20 Euro-Celtique S.A. Formulaciones de agonistas opioides con antagonista liberable y secuestrado.
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
CA2459976A1 (en) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
CN1301104C (zh) * 2002-02-21 2007-02-21 大塚制药株式会社 缓释制剂及其制造方法
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
ES2546010T3 (es) 2002-04-05 2015-09-17 Euro-Celtique S.A. Preparación farmacéutica que contiene oxicodona y naloxona
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
DE60325715D1 (de) * 2002-04-29 2009-02-26 Alza Corp Methoden und darreichungsformen zur kontrollierten freisetzung von oxykodon
RU2004134728A (ru) * 2002-05-31 2005-06-10 Алза Корпорейшн (Us) Дозированные формы и композиции для осмотической доставки различных дозировок оксикодона
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8840928B2 (en) 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
WO2004004693A1 (en) 2002-07-05 2004-01-15 Collgegium Pharmaceutical Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US8557291B2 (en) 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US20040058946A1 (en) * 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
US7168140B2 (en) * 2002-08-08 2007-01-30 Milliken & Company Flame resistant fabrics with improved aesthetics and comfort, and method of making same
CA2495182A1 (en) * 2002-08-15 2004-02-26 Noramco, Inc. Oxycodone-hydrochloride polymorphs
PT1551372T (pt) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc Subunidade de sequestração e composições e métodos relacionados
US20050020613A1 (en) * 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
US20040110781A1 (en) * 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
CA2507522C (en) * 2002-12-13 2015-02-24 Durect Corporation Oral drug delivery system
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
ATE454169T1 (de) * 2003-03-13 2010-01-15 Controlled Chemicals Inc Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
EP1782834A3 (de) * 2003-03-13 2007-08-01 Controlled Chemicals, Inc. Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
ES2360102T3 (es) 2003-03-26 2011-05-31 Egalet A/S Sistema para la liberación controlada de morfina.
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US9579286B2 (en) * 2003-04-21 2017-02-28 Purdue Pharma L.P. Tamper resistant dosage form comprising co-extruded, sequestered adverse agent particles and process of making same
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
CN1826100B (zh) * 2003-07-17 2010-12-22 旗帜药物胶囊公司 控释制剂
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE502004004205D1 (de) * 2003-08-06 2007-08-09 Gruenenthal Gmbh Gegen missbrauch gesicherte darreichungsform
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20050053659A1 (en) * 2003-09-10 2005-03-10 Pace Gary W. Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness
US20050074493A1 (en) * 2003-10-03 2005-04-07 Mehta Atul M. Extended release formulations of opioids and method of use thereof
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US8883204B2 (en) * 2003-12-09 2014-11-11 Purdue Pharma L.P. Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
EP1691892B1 (de) * 2003-12-09 2007-02-28 Euro-Celtique S.A. Coextrudierte sicherheits-dosierform mit einem wirkstoff und einem adversen mittel und herstellungsverfahren dafür
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
BRPI0508769A (pt) * 2004-03-30 2007-08-28 Euro Celtique Sa forma de dosagem resistente a adulteração compreendendo um adsorvente e um agente adverso
TW201509943A (zh) 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
US20050226929A1 (en) * 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
EP1604666A1 (de) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
EP1604667A1 (de) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung des Restless Leg Syndroms
US20070224269A1 (en) * 2004-06-10 2007-09-27 Rubino Orapin P Controlled Release Pharmaceutical Formulation
HUE037643T2 (hu) 2004-06-12 2018-09-28 Collegium Pharmaceutical Inc Visszaélésre nem alkalmas gyógyszerkészítmények
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
US9326959B2 (en) 2004-09-01 2016-05-03 Purdue Pharma, L.P. Opioid dosage forms having dose proportional steady state Cave and AUC and less than dose proportional single dose Cmax
LT2767292T (lt) 2004-09-17 2016-12-12 Durect Corporation Palaikomosios vietinės anestezijos mišinys su saib
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
EP1830886B1 (de) 2004-12-27 2016-04-13 Eisai R&D Management Co., Ltd. Verfahren zur stabilisierung eines arzneimittels gegen demenz
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
CA2594373A1 (en) * 2005-01-28 2006-08-03 Euro-Celtique S.A. Alcohol resistant dosage forms
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1695700A1 (de) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Darreichungsform enthaltend Oxycodon und Naloxon
EP1702558A1 (de) 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
US7884136B2 (en) 2005-06-27 2011-02-08 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
GB2431875A (en) * 2005-10-31 2007-05-09 Alza Corp Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
CN1957909B (zh) * 2005-10-31 2013-09-11 阿尔扎公司 降低鸦片样物质持续释放口服剂型的由醇诱导的剂量突然释放的方法
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
US20100172989A1 (en) * 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
EP3332788A1 (de) 2006-02-03 2018-06-13 Opko Renal, LLC Behandlung von vitamin-d-insuffizienz und -mangel mit 25-hydroxyvitamin d2 und 25-hydroxyvitamin d3
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
CN101400731A (zh) * 2006-03-15 2009-04-01 城北化学工业株式会社 稳定化的聚烯烃类树脂和聚烯烃类树脂的稳定化方法
US20070281016A1 (en) * 2006-06-06 2007-12-06 Endo Pharmaceuticals Inc., A Delaware Corporation Sustained release oxycodone composition with acrylic polymer and surfactant
US20070281017A1 (en) * 2006-06-06 2007-12-06 Endo Pharmaceuticals Inc., A Delaware Corporation Sustained release oxycodone composition with acrylic polymer and metal hydroxide
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
PL2526932T3 (pl) 2006-06-19 2017-12-29 Alpharma Pharmaceuticals Llc Kompozycja farmaceutyczna
ES2670029T3 (es) 2006-06-21 2018-05-29 Opko Ireland Global Holdings, Ltd. Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
KR101445757B1 (ko) * 2006-08-04 2014-10-02 에씨팜 옥시코돈을 포함하는 과립 및 경구 붕해 정제
BRPI0714484A2 (pt) * 2006-08-16 2013-04-24 Auspex Pharmaceuticals Inc composto, mÉtodo de tratar um mamÍfero sofrendo de uma doenÇa ou condiÇço, mÉtodo de tratar um memÍfero sofrendo de uma doenÇa, desordem, sintoma ou condiÇço e composiÇço farmacÊutica
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US8653066B2 (en) 2006-10-09 2014-02-18 Charleston Laboratories, Inc. Pharmaceutical compositions
US8337883B2 (en) 2006-11-03 2012-12-25 Durect Corporation Transdermal delivery systems
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US11752158B2 (en) 2007-04-25 2023-09-12 Eirgen Pharma Ltd. Method of treating vitamin D insufficiency and deficiency
CA2683514C (en) 2007-04-25 2019-07-09 Proventiv Therapeutics, Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
KR101691876B1 (ko) 2007-04-25 2017-01-02 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
US8202542B1 (en) 2007-05-31 2012-06-19 Tris Pharma Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
US20080318994A1 (en) * 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
US20080318993A1 (en) * 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Hepatic Impairment
JP5730572B2 (ja) * 2007-09-13 2015-06-10 シマ ラブス インク． 濫用抵抗性製剤
PT2057984E (pt) 2007-11-09 2010-03-10 Acino Pharma Ag Comprimidos retard com hidromorfona
CA2706658A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions or inflammation associated with a chronic condition
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
EP2240022B1 (de) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Oxycodone und Promethazine enthaltende zweischichtige Tabletten
EP2249811A1 (de) * 2008-01-25 2010-11-17 Grünenthal GmbH Pharmazeutische dosierform
US20090246276A1 (en) 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
KR101094231B1 (ko) 2008-02-18 2011-12-14 하나제약 주식회사 서방성 고형 제제 및 그의 제조방법
WO2009114648A1 (en) 2008-03-11 2009-09-17 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
EP3112476B1 (de) 2008-04-02 2023-08-02 EirGen Pharma Ltd. Verfahren, zusammensetzungen, verwendungen und kits für vitamin-d-mangel und verwandten erkrankungen
US20100004762A1 (en) * 2008-04-24 2010-01-07 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20100125561A1 (en) * 2008-04-24 2010-05-20 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20100041958A1 (en) * 2008-04-24 2010-02-18 Searete Llc Computational system and method for memory modification
US9282927B2 (en) 2008-04-24 2016-03-15 Invention Science Fund I, Llc Methods and systems for modifying bioactive agent use
US9662391B2 (en) * 2008-04-24 2017-05-30 The Invention Science Fund I Llc Side effect ameliorating combination therapeutic products and systems
US20100069724A1 (en) * 2008-04-24 2010-03-18 Searete Llc Computational system and method for memory modification
US20090270694A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring and modifying a combination treatment
US20100130811A1 (en) * 2008-04-24 2010-05-27 Searete Llc Computational system and method for memory modification
US20100081861A1 (en) * 2008-04-24 2010-04-01 Searete Llc Computational System and Method for Memory Modification
US9560967B2 (en) * 2008-04-24 2017-02-07 The Invention Science Fund I Llc Systems and apparatus for measuring a bioactive agent effect
US20100280332A1 (en) * 2008-04-24 2010-11-04 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring bioactive agent use
US9649469B2 (en) * 2008-04-24 2017-05-16 The Invention Science Fund I Llc Methods and systems for presenting a combination treatment
US8876688B2 (en) * 2008-04-24 2014-11-04 The Invention Science Fund I, Llc Combination treatment modification methods and systems
US20100041964A1 (en) * 2008-04-24 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring and modifying a combination treatment
US20090269329A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Combination Therapeutic products and systems
US20090271009A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Combination treatment modification methods and systems
US9239906B2 (en) * 2008-04-24 2016-01-19 The Invention Science Fund I, Llc Combination treatment selection methods and systems
US20090312595A1 (en) * 2008-04-24 2009-12-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System and method for memory modification
US20100076249A1 (en) * 2008-04-24 2010-03-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20090270688A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting a combination treatment
US20100081860A1 (en) * 2008-04-24 2010-04-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational System and Method for Memory Modification
US20090271122A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring and modifying a combination treatment
US20100100036A1 (en) * 2008-04-24 2010-04-22 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational System and Method for Memory Modification
US20090271347A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring bioactive agent use
US20100042578A1 (en) * 2008-04-24 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20100063368A1 (en) * 2008-04-24 2010-03-11 Searete Llc, A Limited Liability Corporation Computational system and method for memory modification
US9026369B2 (en) * 2008-04-24 2015-05-05 The Invention Science Fund I, Llc Methods and systems for presenting a combination treatment
US9449150B2 (en) * 2008-04-24 2016-09-20 The Invention Science Fund I, Llc Combination treatment selection methods and systems
US8930208B2 (en) * 2008-04-24 2015-01-06 The Invention Science Fund I, Llc Methods and systems for detecting a bioactive agent effect
US9064036B2 (en) * 2008-04-24 2015-06-23 The Invention Science Fund I, Llc Methods and systems for monitoring bioactive agent use
US20090312668A1 (en) * 2008-04-24 2009-12-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20090271375A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Combination treatment selection methods and systems
US20100022820A1 (en) * 2008-04-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20100017001A1 (en) * 2008-04-24 2010-01-21 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
HUE030803T2 (en) 2008-05-09 2017-06-28 Gruenenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form using a spraying step \ t
US20090291975A1 (en) * 2008-05-20 2009-11-26 Warren Stern Dual opioid pain therapy
ES2635733T3 (es) * 2008-07-07 2017-10-04 Euro-Celtique S.A. Uso de antagonistas opioideos para tratar la retención urinaria
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
EP3045043B1 (de) 2009-02-26 2020-04-29 Relmada Therapeutics, Inc. Oral einnehmbare pharmazeutische zusammensetzungen aus 3-hydroxy-n-methylmorphinan mit verzögerter freisetzung und verwendungsverfahren dafür
SG174286A1 (en) 2009-03-10 2011-10-28 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US8811578B2 (en) * 2009-03-23 2014-08-19 Telemanager Technologies, Inc. System and method for providing local interactive voice response services
EP2445487A2 (de) 2009-06-24 2012-05-02 Egalet Ltd. Retard-formulierungen
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
EP2456427B1 (de) 2009-07-22 2015-03-04 Grünenthal GmbH Heißschmelzextrudierte retardierte pharmazeutische Darreichungsform
PE20120572A1 (es) * 2009-07-22 2012-06-06 Gruenenthal Chemie Forma de dosificacion de oxidacion estabilizada resistente a la manipulacion
US20110046173A1 (en) * 2009-08-24 2011-02-24 Warren Charles Stern Combination analgesic opioid pain therapy
AU2010286354A1 (en) * 2009-08-31 2012-04-19 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
AU2010300641B2 (en) * 2009-09-30 2016-03-17 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US20110104272A1 (en) * 2009-11-05 2011-05-05 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of acetaminophen and phenylephrine
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
EP2531176B1 (de) * 2010-02-03 2016-09-07 Grünenthal GmbH Herstellung einer pulverförmigen pharmazeutischen zusammensetzung mittels eines extruders
JP5819329B2 (ja) * 2010-03-09 2015-11-24 アルカーメス ファーマ アイルランド リミテッド アルコール耐性腸溶性医薬組成物
HUE048464T2 (hu) 2010-03-29 2020-07-28 Opko Ireland Global Holdings Ltd Módszerek és készítmények mellékpajzsmirigy szintjének csökkentésére
MX2012012991A (es) 2010-05-11 2012-11-30 Cima Labs Inc Formas de dosificacion oral de liberacion prolongada resistentes al alcohol y que contienen metoprolol.
US20120009261A1 (en) 2010-07-06 2012-01-12 Grünenthal GmbH Novel gastro-retentive dosage forms
PE20131126A1 (es) 2010-09-02 2013-10-21 Gruenenthal Chemie Forma de dosificacion resistente a alteracion que comprende un polimero anionico
NZ607392A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising inorganic salt
ES2444591T3 (es) 2010-10-28 2014-02-25 Acino Pharma Ag Medicamento con el principio activo hidromorfona con estabilidad al almacenamiento mejorada
ES2643291T3 (es) 2010-12-22 2017-11-22 Purdue Pharma L.P. Formas de dosificación de liberación controlada con cierre inviolable recubiertas
CA2822769C (en) 2010-12-23 2016-10-04 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
KR20160031038A (ko) 2011-02-02 2016-03-21 알파마 파머슈티컬스 엘엘씨 오피오이드 효능제 및 격리된 길항제를 포함하는 제약 조성물
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
EP4011364B1 (de) 2011-03-23 2023-12-13 Ironshore Pharmaceuticals & Development, Inc. Verfahren und zusammensetzungen zur behandlung von aufmerksamkeitsdefizitsyndrom
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
HUE031251T2 (en) 2011-06-30 2017-07-28 Develco Pharma Schweiz Ag Controlled release oral dosage form containing oxycodone
EP2736495B1 (de) 2011-07-29 2017-08-23 Grünenthal GmbH Verfälschungssichere multipartikular-tablette, die eine sofortige wirkstofffreigabe bereitstellt
DK2736497T3 (da) 2011-07-29 2017-11-13 Gruenenthal Gmbh Stød-resistent tablet, der tilvejebringer en øjeblikkelig frigivelse af et lægemiddel.
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
WO2013153451A2 (en) * 2012-04-09 2013-10-17 QRxPharma Ltd. Controlled release formulations of opioids
CN110101702A (zh) 2012-04-17 2019-08-09 普渡制药公司 用于治疗阿片样物质所致不良药效学响应的系统和方法
LT2838512T (lt) 2012-04-18 2018-11-12 GrĆ¼nenthal GmbH Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
EP2877161A1 (de) 2012-07-06 2015-06-03 Egalet Ltd. Missbrauchssichere pharmazeutische zusammensetzungen zur kontrollierten freisetzung
EP2872121B1 (de) 2012-07-12 2018-09-05 SpecGx LLC Missbrauchssichere pharmazeutische zusammensetzungen mit verzögerter freisetzung
US9101636B2 (en) 2012-11-30 2015-08-11 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
KR101840526B1 (ko) 2013-02-05 2018-03-20 퍼듀 퍼머 엘피 내변조성 제약 제제
CN105120659A (zh) 2013-03-15 2015-12-02 度瑞公司 用于降低溶解可变性的具有流变改性剂的组合物
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
KR20160031526A (ko) 2013-07-12 2016-03-22 그뤼넨탈 게엠베하 에틸렌-비닐 아세테이트 중합체를 함유하는 템퍼 내성 투여형
NZ716267A (en) 2013-07-23 2017-05-26 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
CA2931553C (en) 2013-11-26 2022-01-18 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
AU2015237723B2 (en) 2014-03-26 2018-04-26 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
EP3142646A1 (de) 2014-05-12 2017-03-22 Grünenthal GmbH Manipulationssichere kapselformulierung mit tapentadol mit unmittelbarer freisetzung
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
EP3169315B1 (de) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Missbrauchssichere flüssigkeitsfülldosierform mit unmittelbarer freisetzung
SG10201911274TA (en) 2014-08-07 2020-02-27 Opko Ireland Global Holdings Ltd Adjunctive therapy with 25-hydroxyvitamin d
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CA2936740C (en) 2014-10-31 2017-10-10 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
JP2019507181A (ja) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
TWI747893B (zh) 2016-03-28 2021-12-01 愛爾蘭商歐科愛爾蘭全球控股股份有限公司 維生素ｄ治療之方法
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2019087084A1 (en) 2017-11-02 2019-05-09 Eman Biodiscoveries Sd. Bhd. Extract of orthosiphon stamineus, formulations, and uses thereof
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
WO2020225773A1 (en) 2019-05-07 2020-11-12 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CN115702888A (zh) * 2021-08-13 2023-02-17 合肥立方制药股份有限公司 一种盐酸羟考酮渗透泵缓释片及其制备方法

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US291883A (en) * 1884-01-15 Faucet
US2738303A (en) * 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
US2921883A (en) * 1957-05-03 1960-01-19 Smith Kline French Lab Novel coating material for medicaments
NL263733A (de) * 1960-04-19 1900-01-01
US4132753A (en) * 1965-02-12 1979-01-02 American Cyanamid Company Process for preparing oral sustained release granules
US3458622A (en) * 1967-04-07 1969-07-29 Squibb & Sons Inc Controlled release tablet
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US3634584A (en) * 1969-02-13 1972-01-11 American Home Prod Sustained action dosage form
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
GB1405088A (en) † 1971-06-03 1975-09-03 Mundipharma Ag Slow release formulation
US3773920A (en) * 1971-07-14 1973-11-20 Nikken Chemicals Co Ltd Sustained release medicinal composition
US3965256A (en) * 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3922339A (en) * 1974-06-20 1975-11-25 Kv Pharm Co Sustained release medicant
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US3946899A (en) * 1975-02-07 1976-03-30 Allain Charles V Sugar cane planter
JPS5535031A (en) * 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
WO1980000659A1 (en) * 1978-10-02 1980-04-17 Purdue Research Foundation Food and pharmaceutical coating composition,method of preparation and products so coated
IE48715B1 (en) * 1978-12-22 1985-05-01 Elan Corp Plc New galencial forms for administration of medicaments by oral route,with programmed release and processes for preparing same
FI63335B (fi) * 1979-02-02 1983-02-28 Orion Yhtymae Oy Foerfarande foer framstaellning av tabletter med foerdroejd loslighet av effektaemne
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
DE3024416C2 (de) * 1980-06-28 1982-04-15 Gödecke AG, 1000 Berlin Verfahren zur Herstellung von Arzneimitteln mit retardierter Wirkstoff-Freisetzung
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
US4377568A (en) * 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
US4369172A (en) † 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
DE3208791A1 (de) * 1982-03-11 1983-09-22 Röhm GmbH, 6100 Darmstadt Verfahren zum ueberziehen von arzneiformen mittes eines in wasser dispergierten ueberzugsmittels
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
DE3314003A1 (de) * 1983-04-18 1984-10-18 Boehringer Ingelheim KG, 6507 Ingelheim Teilbare tablette mit verzoegerter wirkstofffreigabe und verfahren zu deren herstellung
US4548990A (en) * 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4894234A (en) * 1984-10-05 1990-01-16 Sharma Shri C Novel drug delivery system for antiarrhythmics
JPS61152765A (ja) * 1984-12-27 1986-07-11 Nippon Ekishiyou Kk シクロデキストリン類で包接された化合物を含有した合成樹脂製品及びその製造方法
US4600645A (en) * 1985-01-31 1986-07-15 Warner-Lambert Company Process for treating dosage forms
NL8500724A (nl) * 1985-03-13 1986-10-01 Univ Groningen Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.
ATE84713T1 (de) * 1985-05-13 1993-02-15 Miles Inc Verwendung von kalziumantagonisten zur anfertigung von zusammensetzungen fuer entziehungssymptome.
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
EP0249347B1 (de) † 1986-06-10 1994-06-29 Euroceltique S.A. Zusammensetzung mit kontrollierter Freisetzung von Dihydrocodein
US4970075A (en) † 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5266311A (en) * 1987-05-28 1993-11-30 Immunex Corporation Bovine interleukin-1α
US5219575A (en) * 1987-06-26 1993-06-15 Duphar International Research B.V. Compositions with controlled zero-order delivery rate and method of preparing these compositions
DE3721721C1 (de) * 1987-07-01 1988-06-09 Hoechst Ag Verfahren zur Umhuellung von Granulaten
US5068110A (en) * 1987-09-29 1991-11-26 Warner-Lambert Company Stabilization of enteric coated dosage form
US4862598A (en) * 1987-10-01 1989-09-05 Perceptron, Inc. Quick connect/disconnect repeatable sensor mounting apparatus
US5019397A (en) * 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
JPH01287019A (ja) * 1988-05-12 1989-11-17 Tanabe Seiyaku Co Ltd 徐放性製剤
JP2681373B2 (ja) * 1988-07-18 1997-11-26 塩野義製薬株式会社 徐放性製剤の製造法
JP2850376B2 (ja) * 1988-08-02 1999-01-27 日産化学工業株式会社 抗癌剤薬効増強剤
US4983730A (en) * 1988-09-02 1991-01-08 Hoechst Celanese Corporation Water soluble cellulose acetate composition having improved processability and tensile properties
US5178868A (en) * 1988-10-26 1993-01-12 Kabi Pharmacia Aktiebolaq Dosage form
US5196203A (en) * 1989-01-06 1993-03-23 F. H. Faulding & Co. Limited Theophylline dosage form
US5330766A (en) * 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5122384A (en) * 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
FR2648020B1 (fr) * 1989-06-12 1992-03-13 Rhone Poulenc Sante Utilisation de compositions degradables par voie enzymatique pour l'enrobage d'additifs alimentaires destines aux ruminants
DK161743C (da) * 1989-07-03 1992-02-17 Niro Atomizer As Fremgangsmaade og apparat til agglomerering af et pulverformigt materiale
EP0418596A3 (en) * 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5248516A (en) * 1989-12-19 1993-09-28 Fmc Corporation Film-forming composition: method of producing same and use for coating pharmaceuticals and foods and the like
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
US5206030A (en) * 1990-02-26 1993-04-27 Fmc Corporation Film-forming composition and use for coating pharmaceuticals, foods and the like
JP2542122B2 (ja) * 1990-04-18 1996-10-09 旭化成工業株式会社 球状核、球形顆粒およびその製造方法
DK0472502T3 (da) * 1990-08-24 1995-10-09 Spirig Ag Fremgangsmåde til fremstilling af pellets
JP2669945B2 (ja) * 1991-02-05 1997-10-29 ファナック株式会社 ならい制御装置
US5132142A (en) * 1991-03-19 1992-07-21 Glatt Gmbh Apparatus and method for producing pellets by layering power onto particles
CA2108575C (en) * 1991-04-16 2002-10-22 Kouichi Nakamichi Method of manufacturing solid dispersion
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5215758A (en) * 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5273760A (en) † 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5286493A (en) † 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
SE9202250D0 (sv) * 1992-07-29 1992-07-29 Gacell Lab Ab Controlled release morphine preparation
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
SE9301057L (sv) * 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
DE4329794C2 (de) * 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US5460826A (en) * 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5811126A (en) * 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations

Also Published As

Publication number Publication date
EP1325746A1 (de) 2003-07-09
HU227815B1 (en) 2012-03-28
PL173574B1 (pl) 1998-03-31
PT1502592E (pt) 2007-09-17
NO932661L (no) 1993-09-24
FI118252B (fi) 2007-09-14
FI116658B (fi) 2006-01-31
ES2268189T3 (es) 2007-03-16
EP1810679A3 (de) 2007-10-03
DK1327446T4 (da) 2007-12-17
HK1059210A1 (en) 2004-06-25
ES2215983T3 (es) 2004-10-16
DK1438959T3 (da) 2007-09-17
US5508042A (en) 1996-04-16
NO20041662L (no) 1993-09-24
IL103909A0 (en) 1993-04-04
SK280295B6 (sk) 1999-11-08
NO318890B1 (no) 2005-05-18
ES2287625T3 (es) 2007-12-16
DK1325746T3 (da) 2006-11-06
DE69233640D1 (de) 2006-08-24
HK1051803A1 (en) 2003-08-22
ES2215984T5 (es) 2008-03-16
FI20031888A (fi) 2003-12-22
ATE144418T1 (de) 1996-11-15
EP1258246A2 (de) 2002-11-20
EP1258246B1 (de) 2004-03-17
JPH06507645A (ja) 1994-09-01
BG97973A (bg) 1994-05-27
NO932661D0 (no) 1993-07-23
DK0722730T3 (da) 2002-11-25
FI933330A0 (fi) 1993-07-23
PT1327445E (pt) 2004-07-30
AU3147693A (en) 1993-06-28
DE69233326T2 (de) 2005-03-10
DK0576643T3 (da) 1997-04-21
DE69233778D1 (de) 2010-02-25
SK92293A3 (en) 1994-04-06
NO307028B3 (no) 2009-05-25
DE69233327T2 (de) 2005-03-10
ES2213720T3 (es) 2004-09-01
HU0400357D0 (en) 2004-04-28
NO322378B1 (no) 2006-09-25
ES2096781T3 (es) 1997-03-16
EP1327446A1 (de) 2003-07-16
NO20041667L (no) 1993-09-24
US5549912A (en) 1996-08-27
EP1438959B1 (de) 2007-04-25
EP1327446B1 (de) 2004-03-17
EP1502592A1 (de) 2005-02-02
EP0722730B2 (de) 2013-08-07
US20060057210A1 (en) 2006-03-16
DE9219234U1 (de) 2001-03-29
EP2243484A2 (de) 2010-10-27
ES2339392T3 (es) 2010-05-19
HU227515B1 (en) 2011-07-28
ATE365041T1 (de) 2007-07-15
AU657027B2 (en) 1995-02-23
US20060099255A1 (en) 2006-05-11
EP1327445A1 (de) 2003-07-16
ATE261726T1 (de) 2004-04-15
ATE226822T1 (de) 2002-11-15
EP0722730A1 (de) 1996-07-24
HK1068004A1 (en) 2005-04-22
CA2098738A1 (en) 1993-05-28
GR3022273T3 (en) 1997-04-30
DE69232837D1 (de) 2002-12-05
WO1993010765A1 (en) 1993-06-10
PT1325746E (pt) 2006-11-30
MX9302968A (es) 1994-05-31
EP1327446B2 (de) 2007-08-22
EP1327445B1 (de) 2004-03-17
EP1810679A2 (de) 2007-07-25
DE69233326D1 (de) 2004-04-22
EP2106796A3 (de) 2009-11-04
ATE261725T1 (de) 2004-04-15
ZA929227B (en) 1993-07-12
YU49495B (sh) 2006-08-17
NO20041939L (no) 1993-05-27
DE69214802D1 (de) 1996-11-28
EP2106796A2 (de) 2009-10-07
HU227514B1 (en) 2011-07-28
EP1774969A2 (de) 2007-04-18
HU227518B1 (en) 2011-07-28
FI933330A (fi) 1993-07-23
HU0400225D0 (en) 2004-04-28
US20040105887A1 (en) 2004-06-03
HU0303097D0 (en) 2003-11-28
ES2215984T3 (es) 2004-10-16
PT1438959E (pt) 2007-07-19
DE69233699T2 (de) 2008-02-28
CN1364458A (zh) 2002-08-21
NO323334B1 (no) 2007-03-26
PT1810679E (pt) 2010-02-18
EP2243484A3 (de) 2012-01-11
IL103909A (en) 1996-09-12
HK1059209A1 (en) 2004-06-25
US20020018810A1 (en) 2002-02-14
EP2340833A3 (de) 2012-09-12
NO996447L (no) 1993-09-24
BR9205498A (pt) 1994-06-07
DE69214802T2 (de) 1997-05-07
HK1058474A1 (en) 2004-05-21
CN1087262A (zh) 1994-06-01
FI20031890A (fi) 2003-12-22
CZ300183B6 (cs) 2009-03-11
HK1073255A1 (en) 2005-09-30
RS50056B (sr) 2008-11-28
EP1774969A3 (de) 2007-10-03
EP1810679B1 (de) 2010-01-06
NO20043264L (no) 1993-09-24
DK0576643T5 (da) 2004-11-22
EP2289517B1 (de) 2014-05-07
HU0400224D0 (en) 2004-04-28
PT722730E (pt) 2003-03-31
EP1502592B1 (de) 2007-06-20
CZ298499B6 (cs) 2007-10-17
KR100280973B1 (ko) 2001-02-01
ES2186737T3 (es) 2003-05-16
EP0722730B1 (de) 2002-10-30
PT1327446E (pt) 2004-06-30
DK0722730T4 (da) 2013-11-18
EP1438959A1 (de) 2004-07-21
DK1327446T3 (da) 2004-08-02
CZ286913B6 (cs) 2000-08-16
PH31679A (en) 1999-01-18
EP0576643A4 (de) 1994-03-18
EP2106797A3 (de) 2009-11-04
EP0576643B1 (de) 1996-10-23
HU0302920D0 (en) 2003-11-28
US5266331A (en) 1993-11-30
HU0400227D0 (en) 2004-04-28
HU224075B1 (hu) 2005-05-30
DE69232837T2 (de) 2003-06-18
PL172236B1 (pl) 1997-08-29
HU227517B1 (en) 2011-07-28
DK1810679T3 (da) 2010-02-08
DK0722730T5 (da) 2003-03-31
DE69232837T3 (de) 2014-01-02
DE69233691T2 (de) 2008-01-24
EP0576643A1 (de) 1994-01-05
EP2340833A2 (de) 2011-07-06
ES2186737T5 (es) 2014-01-17
HU9301517D0 (en) 1993-09-28
HU227516B1 (en) 2011-07-28
ATE454150T1 (de) 2010-01-15
US20040185098A1 (en) 2004-09-23
RS50055B (sr) 2008-11-28
CA2098738C (en) 1999-08-17
EP1325746B1 (de) 2006-07-12
FI118251B (fi) 2007-09-14
EP2106797A2 (de) 2009-10-07
DE69233328T3 (de) 2008-02-07
DK200000364U3 (da) 2001-03-23
EP2289517A2 (de) 2011-03-02
DE69233328D1 (de) 2004-04-22
JP2002370983A (ja) 2002-12-24
EP1258246A3 (de) 2003-01-08
BG61753B1 (bg) 1998-05-29
US20040096500A1 (en) 2004-05-20
FI20031891A (fi) 2003-12-22
HU228058B1 (en) 2012-09-28
CN1245958C (zh) 2006-03-22
CN1165307C (zh) 2004-09-08
JP3375960B2 (ja) 2003-02-10
NO996447D0 (no) 1999-12-23
HU226929B1 (en) 2010-03-01
DE69233640T2 (de) 2007-06-14
DK1502592T3 (da) 2007-10-22
CZ176493A3 (en) 1994-04-13
FI113152B (fi) 2004-03-15
YU35893A (sh) 1997-03-07
DE69233328T2 (de) 2005-03-10
US20060165791A1 (en) 2006-07-27
DK1258246T3 (da) 2004-07-05
NO325483B1 (no) 2008-05-13
CZ292849B6 (cs) 2003-12-17
HU0401532D0 (en) 2004-09-28
RS50054B (sr) 2008-11-28
NO307028B1 (no) 2000-01-31
US20030099704A1 (en) 2003-05-29
HU0400226D0 (en) 2004-04-28
FI20031889A (fi) 2003-12-22
EP2289517A3 (de) 2012-07-04
DK1327445T3 (da) 2004-07-26
DE69233699D1 (de) 2007-08-02
DE69233327D1 (de) 2004-04-22
PT1258246E (pt) 2004-06-30
ES2286523T3 (es) 2007-12-01
FI118250B (fi) 2007-09-14
JP4016074B2 (ja) 2007-12-05
ATE261727T1 (de) 2004-04-15
ATE360421T1 (de) 2007-05-15
ATE332691T1 (de) 2006-08-15
US20060165792A1 (en) 2006-07-27
US20010008639A1 (en) 2001-07-19
HUT69401A (en) 1995-09-28
RO115112B1 (ro) 1999-11-30
RU2122411C1 (ru) 1998-11-27

Similar Documents

Publication Publication Date Title
DE69233699D1 (de) Oxycodonzusammensetzungen mit kontrollierter Freisetzung

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: MUNDIPHARMA GMBH, 65549 LIMBURG, DE

8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 1438959

Country of ref document: EP